Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 64 for your search:
Cancer Type/Condition:
Nasopharyngeal cancer
Stage/Subtype:
stage III nasopharyngeal cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
NCI
Protocol IDs:
COG-ARAR0331
, ARAR0331, NCT00274937
2.
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
UCIRB #14735B
, GV-001.010 (TNF-ELF), NCT00496236
3.
A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
UCIRB #14733B
, GV-001.011 (TNF-CORE), NCT00496535
4.
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-069
, NCT00570674
5.
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MCC-15461
, IND 102483, LBH589, NCT00738751
6.
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR015580
, NCT00841191
7.
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
603EUSA03
, NCT00901732
8.
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO # 06-0509
, NCT00970502
9.
A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
J0916
, NA_00023951, NCT01009346
10.
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
OSU-0482
, NCT00293579
11.
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
H-26154 (GCC 0442)
, CA225092, NCT00343083
12.
Use of Cone Beam Kilovaltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06U.195
, NCT00358007
13.
Cisplatin and Radiation Therapy With or Without Erlotinib in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UWCC-6106
, 6106, UWCC-05-9278-H/B, GENENTECH-OSI3602s, FHCRC-6106, NCT00410826
14.
Fluorouracil, Hydroxyurea, Cetuximab and Twice-Daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO 06-1155
, NCT00462735
15.
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
14401A
, NCT00468169
16.
Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
ENT0020
, 97864, ENT0020, LAP #109855, NCT00490061, NCT00490061
17.
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
05-089
, NCT00592501
18.
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
Phase:
Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
08-0285
, NCT00671437
19.
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CASE-5307
, CASE5307, SANOFI-AVENTIS-CASE-5307, CASE-IRB-05-02-12, NCT00720304
20.
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-050
, NCT00713219
21.
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0153
, OSI4178S, NCT00750555
22.
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 015
, NCT00753038
23.
Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
GRID
, NCT00765570
24.
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, and Radiation Therapy in Treating Patients With Advanced Nasopharyngeal Carcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SUMC-ENT 0025
, ENT 0025, 8209, NCT00841997
25.
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
UWCC-6862
, UWCC-6862, IR-6862, NCT00895245
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
